HSIC

Henry Schein's systematic profile reveals a healthcare distribution business operating with distinctive margin discipline relative to sector norms. The company's net margin of 2.95% and operating margin of 4.93% reflect the capital-efficient intermediary model typical of medical supply distributors, while the current valuation at 0.62x price-to-sales indicates market pricing below premium peer multiples. Trading at $72.69 within its 52-week range of $61.95 to $89.29, the equity sits approximately 19% below its recent peak.

The fundamental screener highlights several structural attributes worth noting:

• Leverage positioning: The debt-to-equity ratio of 0.96 positions HSIC near parity, balanced by a current ratio of 1.38 that indicates adequate short-term liquidity management for working capital-intensive distribution operations
• Return profile: ROE of 11.86% and ROA of 3.55% demonstrate moderate capital efficiency, with the spread reflecting the company's use of financial leverage to enhance shareholder returns
• Growth trajectory: Revenue expansion of 5.64% year-over-year outpaces EPS growth of 2.93%, suggesting margin compression or increased operating investment during the period
• Valuation compression: The trailing P/E of 20.97 combined with book value per share of $28.03 yields a price-to-book of 2.77, moderately elevated for a distributor with single-digit ROA

Research perspectives relative to peers McKesson (MCK), Cencora (COR), and Cardinal Health (CAH) position HSIC with comparable margin economics but materially smaller scale at $8.3 billion market capitalization. The beta of 0.83 indicates below-market volatility, consistent with essential healthcare supply chain businesses.